Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Investment analysts at Svb Leerink raised their FY2020 earnings per share estimates for shares of Ionis Pharmaceuticals in a research note issued on Wednesday, November 6th. Svb Leerink analyst M. Foroohar now anticipates that the company will post earnings of $0.62 per share for the year, up from their prior estimate of $0.52.
A number of other equities analysts have also recently weighed in on IONS. BMO Capital Markets decreased their price target on Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, July 24th. Piper Jaffray Companies decreased their price target on Ionis Pharmaceuticals from $75.00 to $70.00 and set a “neutral” rating for the company in a report on Thursday. TheStreet cut Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and issued a $87.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday. Finally, Cantor Fitzgerald set a $65.00 price target on Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, October 15th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $73.45.
NASDAQ IONS traded up $1.71 on Friday, reaching $57.06. The company had a trading volume of 925,100 shares, compared to its average volume of 1,150,599. The firm has a market capitalization of $7.64 billion, a PE ratio of 19.28, a P/E/G ratio of 15.24 and a beta of 1.90. Ionis Pharmaceuticals has a 1 year low of $48.27 and a 1 year high of $86.58. The firm has a 50-day moving average of $57.99 and a 200-day moving average of $64.32. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.01 and a quick ratio of 9.93.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.49. The firm had revenue of $168.00 million during the quarter, compared to analysts’ expectations of $152.47 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. Ionis Pharmaceuticals’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.03) EPS.
In other news, Chairman Stanley T. Crooke sold 22,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $71.52, for a total transaction of $1,573,440.00. Following the completion of the transaction, the chairman now directly owns 79,634 shares in the company, valued at approximately $5,695,423.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 2.40% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in IONS. Whittier Trust Co. boosted its stake in shares of Ionis Pharmaceuticals by 283.0% during the 2nd quarter. Whittier Trust Co. now owns 383 shares of the company’s stock valued at $25,000 after buying an additional 283 shares during the last quarter. CWM LLC boosted its stake in shares of Ionis Pharmaceuticals by 361.4% during the 2nd quarter. CWM LLC now owns 406 shares of the company’s stock valued at $26,000 after buying an additional 318 shares during the last quarter. Ellis Investment Partners LLC purchased a new position in shares of Ionis Pharmaceuticals during the 2nd quarter valued at approximately $32,000. Quest Capital Management Inc. ADV purchased a new position in shares of Ionis Pharmaceuticals during the 3rd quarter valued at approximately $36,000. Finally, Rehmann Capital Advisory Group boosted its stake in shares of Ionis Pharmaceuticals by 41.3% during the 2nd quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock valued at $38,000 after buying an additional 173 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Further Reading: Momentum Indicators
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.